[F-18]-DCFPyL Injection (“[F-18]-DCFPyL”) is a novel, urea-based, small molecule imaging biomarker that targets prostate-specific membrane antigen (PSMA). PSMA is overexpressed in prostate cancer, particularly in poorly-differentiated, hormone-independent and metastatic disease; this makes PSMA a useful target in patients with more aggressive forms of prostate cancer.
In combination with positron emission tomography (PET), [F-18]-DCFPyL has potential as a tool to guide treatment planning, predict treatment response and inform about the prognosis in patients with primary and metastatic prostate cancer.
Maurer T, Eiber M, Schwaiger M et al. Current use of PSMA-PET in prostate cancer management. Nature Reviews Urology. 2016; 13(4): 226-235.
Szabo Z, Mena E, Rowe SP et al. Initial Evaluation of 18F-DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol. 2015; 17(4): 565-574.
Dietlein M, Kobe C, Kuhnert G et al. Comparison of 18F-DCFPyL and 68Ga-PSMA-HBED-CC for PSMA PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol. 2015; 17(4): 575-584.
These references are provided for informational purposes only and do not represent an endorsement for any particular clinical use.
The safety and efficacy of [F-18]-DCFPyL Injection have not been fully established and it has not been approved by Health Canada as a commercial product for medicinal use. It is an investigational drug product and can only be used under an approved clinical trial application (CTA). Please contact the CPDC if you require further information.